🇺🇸 FDA
Pipeline program

SODIUM CHLORIDE, ARO-DUX4

ARODUX4-1001

Phase 2 small_molecule active

Quick answer

SODIUM CHLORIDE, ARO-DUX4 for Facioscapulohumeral muscular dystrophy (FSHD) is a Phase 2 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Facioscapulohumeral muscular dystrophy (FSHD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials